2021 ACCP Virtual Journal Club August | Differential Binding of Sarilumab and Tocilizumab to IL-6Rα and Effects of Receptor Occupancy on Clinical Parameters- LIVE
Includes a Live Event on 08/18/2021 at 2:00 PM (EDT)
Differential Binding of Sarilumab and Tocilizumab to IL-6Rα and Effects of Receptor Occupancy on Clinical Parameters- LIVE
ACCP Virtual Journal Club Webinars
Live Session: Wednesday, August 18, 2021 from 2:00-3:00 PM ET
On Demand: August 18, 2021 to August 18, 2024
See Handouts tab for Continuing Education information on IPCE credits.
Why is this webinar important to you?
This webinar will present the bridging through pharmacokinetic/pharmacodynamic modeling the in vitro binding affinity to in vivo receptor occupancy and the potential association with clinical parameter improvements of sarilumab and tocilizumab in patients with rheumatoid arthritis. The study evaluated the in vitro binding of sarilumab and tociluzumab to interleukin (IL)-6Rα and inhibition of signaling and the association between IL-6Rα receptor occupancy and C-reactive protein (CRP) and potential clinical relevance of differences.
Interprofessional team of Physicians, Pharmacists, PhDs, Nurse Practitioners and Physician Assistants.
After completing this activity, the learner will be able to:
1) Articulate the mechanism of action of sarilumab and tocilizumab and the downward physiologic effects;
2) Differentiate the binding affinity of sarilumab and tocilizumab to IL-6Rα compared to placebo;
3) Evaluate the expected response to CRP levels and the expected clinical response based on dosage and usage of sarilumab and tocilizumab.
To receive credit, learners must attend the complete live webinar or view the complete on-demand webinar; complete a post-course assessment and evaluation.
Christine R. Xu, PhD
Director, Translational Medicine & Early Development
Dr. Christine Xu, is currently a Director in the Translational Medicine & Early Development Dept at Sanofi. She has supported the development portfolio across several therapeutic areas including immunology, oncology, virology and neuroscience. She served as a project team leader in many development teams, has successfully led development programs from the First-in-Human studies to life cycle management and contributed to global filings, including IND/IMPD and NDA/BLA at Sanofi, Schering-Plough/Merck and Valeant in the past 19 years. Her research interests include clinical pharmacology and model-informed drug development and has implemented quantitative approaches including population PK, translational PK/PD, clinical PK/PD modeling and analysis, physiological-based PK (PBPK) modeling and simulation, DDI predictions, as well as pediatric drug development strategies. Christine Xu holds a PhD in Pharmaceutical Chemistry from the National Univ of Singapore and has post-doc training from the Univ of Kansas. She has authored approximately 70 research papers, book chapters and 100 conference abstracts and presentations.
Alexander J. Sperry, BS, PharmD (Moderator)
Clinical Research Fellow
Medical Coll of Wisconsin
Dr. Alex Sperry grew up in Beach Park, Illinois. He received his Bachelor of Science in Biochemistry at Carroll Univ and then received his PharmD from the Medical Coll of Wisconsin. Alex is currently completing his post-doctoral work as a Clinical Research Fellow at the East Coast Inst for Research. Alex’s role involves enrolling patients in various clinical trials and compiling data for various pharmaceutical sponsors. Alex’s love for clinical research started during pharmacy school when he had the opportunity to work with nanoparticle-based drug delivery systems. He is interested in Phase II-IV clinical trials involving diabetes, immunology, oncology and alternative drug delivery systems/devices.
|Access Date||Quiz Result||Score||Actions|